The analyst said the two companies are likely to end up cross-licensing a number of patents, and Friday's verdict means Boston Scientific could be entitled to royalties on sales of J&J's Cypher stents.
The ruling "is a good start" for Boston Scientific, but it will take a while for the dispute to come to a conclusion, said Mark Landy, an analyst with Susquehanna Financial Group.
The jury found that J&J's Cypher drug-coated stent infringes one Boston Scientific patent and that the company's Cypher, Bx Velocity, Bx Sonic, and Genesis stents infringe a second patent.
The court has not yet set a date for when damages would be determined.
What, Guidant isn't guilty? Guidant is criminally negligent? GDT is the bunch of thugs you speak about. Just check out their corporate history. If JNJ is so farking high and mighty, they would have pulled the plug on GDT when the facts came out. Or did JNJ know in advance? Point is business is business, no matter what your credo tries to paint the company as.